Danaher posted a robust Q3 2026 with revenue of $6.554B (+8.5% YoY) and adjusted EPS of $2.11, beating expectations. The company raised full-year non-GAAP EPS guidance to $8.57–$8.62 and expects Q4 core revenue growth of about 3% after a ~150 basis point respiratory headwind. The results reinforce the DBS-driven operating leverage and Danaher’s leadership position in life sciences and diagnostics, supporting near-term upside if growth trends persist.
Danaher unveiled plans to launch its first AI-powered autonomous research lab early next year, a move aimed at accelerating drug discovery and development. The initiative could lift R&D productivity and shorten development timelines, potentially strengthening the pipeline and long-term margins, though no financial details or milestones were disclosed.
Danaher raised its annual profit forecast on Tuesday, signaling earnings strength, but trimmed its core revenue growth outlook and posted weaker-than-expected biotechnology revenue, triggering roughly a 12% premarket drop. The divergence between stronger profitability and slower top-line growth suggests near-term stock pressure despite solid margins, with outcome hinges on biotech momentum and potential for guidance revision if conditions improve.
Danaher reported a solid Q2 with revenue at $6.3B and net earnings of $870M ($1.23 per share), up 60% YoY, along with an 8% rise in non-GAAP EPS to $1.94. Core revenue rose 3.0% (4.5% excluding respiratory testing), and operating cash flow was $1.5B. The Masimo acquisition has closed earlier than expected, enabling a higher full-year EPS target of $8.45–$8.60, while the company also updates guidance for 3Q and full-year core sales growth. A new non-GAAP metric, core sales excluding respiratory testing, was introduced to better reflect underlying growth, and tariff refunds will be excluded from core starting in Q3 2026.
Danaher Corporation has priced a €2.98 billion senior notes offering to finance its acquisition of Masimo Corporation. This capital raise could strengthen Danaher's balance sheet and accelerate its strategic growth in the life sciences sector.
Danaher Corporation reported solid Q1 2026 results, with net earnings of $1.0 billion and a 9.5% increase in adjusted EPS to $2.06. The company also raised its full-year EPS guidance to $8.35-$8.55, and announced an acquisition of Masimo Corporation, expected to enhance its healthcare offerings.
